Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based study
DOI:
https://doi.org/10.2340/sju.v61.45652Keywords:
metastatic prostate cancer, doublet therapy, triplet therapy, androgen deprivation therapy, chemotherapy, androgen receptor pathway inhibitorAbstract
Purpose: In randomised clinical trials, doublet and triplet therapy improved survival compared to standard androgen deprivation therapy (ADT) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC). Guidelines recommend doublet therapy since 2020 and triplet therapy since 2022. The aim of this study was to assess the uptake of upfront doublet and triplet therapy at a population level and assess trends in survival for all men with mCSPC.
Methods: We included men registered with de novo mCSPC in 2016–2024 in the National Prostate Cancer Register of Sweden. We estimated the annual proportion of men with de novo mCSPC who upfront received doublet therapy (ADT plus androgen receptor pathway inhibitor [ARPI] or docetaxel) or triplet therapy (ADT plus docetaxel and ARPI). Kaplan–Meier curves were used to estimate 3-year overall survival.
Results: In 9294 men diagnosed with de novo mCSPC, the use of upfront doublet therapy increased from 19% in 2016 to 66% in 2024, and the use of triplet therapy rose from 4% in 2021 to 17% in 2024. Uptake was highest among men below age 65 years, of whom 46% received doublet and 48% received triplet therapy in 2024. Three-year survival increased from 51% (95% CI: 49–52%) in 2016–2018 to 61% (95% CI: 58–64%) in 2022–2024. Among men below age 65, survival increased from 69% (95% CI: 65–73) in 2019–2021 to 77% (95% CI: 71–84) in 2022–2024.
Conclusions: The uptake of doublet and triplet therapy increased substantially during the study period, in particular among men below age 65. In parallel, 3-year overall survival increased in all men diagnosed with de novo mCSPC. These data provide support for the benefit of upfront doublet or triplet therapy in clinical practice.
Downloads
References
Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77(3):365–372.
https://doi.org/10.1016/j.eururo.2019.09.004 DOI: https://doi.org/10.1016/j.eururo.2019.09.004
James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351.
https://doi.org/10.1056/NEJMoa1702900 DOI: https://doi.org/10.1056/NEJMoa1702900
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
https://doi.org/10.1056/NEJMoa1704174 DOI: https://doi.org/10.1056/NEJMoa1704174
Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–256.
https://doi.org/10.1016/S1470-2045(15)00489-1 DOI: https://doi.org/10.1016/S1470-2045(15)00489-1
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695–1707.
https://doi.org/10.1016/S0140-6736(22)00367-1 DOI: https://doi.org/10.1016/S0140-6736(22)00367-1
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–1142.
https://doi.org/10.1056/NEJMoa2119115 DOI: https://doi.org/10.1056/NEJMoa2119115
Jian T, Zhan Y, Hu K, et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Front Pharmacol. 2022;13:955925.
https://doi.org/10.3389/fphar.2022.955925 DOI: https://doi.org/10.3389/fphar.2022.955925
Schaeffer EM, Srinivas S, Adra N, et al. NCCN guidelines® insights: prostate cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140–150.
Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II – 2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164–182.
https://doi.org/10.1016/j.eururo.2024.04.010 DOI: https://doi.org/10.1016/j.eururo.2024.04.010
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284.
https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642.
https://doi.org/10.1016/j.eururo.2016.08.002 DOI: https://doi.org/10.1016/j.eururo.2016.08.002
Corsini C, Garmo H, Orrason AW, et al. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604.
https://doi.org/10.1001/jamanetworkopen.2023.36604 DOI: https://doi.org/10.1001/jamanetworkopen.2023.36604
Schoen MW, Doherty J, Eaton D, et al. Treatment patterns and survival among veterans with de novo metastatic hormone-sensitive prostate cancer. JAMA Netw Open. 2025;8(5):e259433.
https://doi.org/10.1001/jamanetworkopen.2025.9433 DOI: https://doi.org/10.1001/jamanetworkopen.2025.9433
Raval AD, Chen S, Littleton N, et al. Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU Int. 2025;135(3):408–421.
https://doi.org/10.1111/bju.16577 DOI: https://doi.org/10.1111/bju.16577
Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190–192.
https://doi.org/10.2340/sju.v59.42272 DOI: https://doi.org/10.2340/sju.v59.42272
Stranne J. 2023/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210–211.
https://doi.org/10.2340/sju.v59.42656 DOI: https://doi.org/10.2340/sju.v59.42656
Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158–163.
https://doi.org/10.3109/0284186X.2014.939299 DOI: https://doi.org/10.3109/0284186X.2014.939299
Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–111.
https://doi.org/10.1016/j.ejca.2014.10.025 DOI: https://doi.org/10.1016/j.ejca.2014.10.025
Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: The National Prostate Cancer Register of Sweden and prostate cancer data base – a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.
https://doi.org/10.1093/ije/dyv305 DOI: https://doi.org/10.1093/ije/dyv305
Westerberg M, Holm L, Garmo H, et al. Cohort profile update: the National Prostate Cancer Register of Sweden and PCBase. Int J Epidemiol. 2025;54(5):dyaf172.
https://doi.org/10.1093/ije/dyaf172 DOI: https://doi.org/10.1093/ije/dyaf172
Gedeborg R, Sandin F, Thellenberg-Karlsson C, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58:9578.
https://doi.org/10.2340/sju.v58.9572 DOI: https://doi.org/10.2340/sju.v58.9572
Ventimiglia E, Gedeborg R, Orrason AW, et al. A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer. Scand J Urol. 2025;60:105–107.
https://doi.org/10.2340/sju.v60.43810 DOI: https://doi.org/10.2340/sju.v60.43810
Westerberg M, Irenaeus S, Garmo H, et al. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804.
https://doi.org/10.1371/journal.pone.0296804 DOI: https://doi.org/10.1371/journal.pone.0296804
Westerberg M, Garmo H, Robinson D, et al. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504.
https://doi.org/10.1016/j.jclinepi.2024.111504 DOI: https://doi.org/10.1016/j.jclinepi.2024.111504
Gedeborg R, Sund M, Lambe M, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607–615.
https://doi.org/10.1097/EDE.0000000000001358 DOI: https://doi.org/10.1097/EDE.0000000000001358
Fallara G, Gedeborg R, Bill-Axelson A, et al. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16(7):e0255239.
https://doi.org/10.1371/journal.pone.0255239 DOI: https://doi.org/10.1371/journal.pone.0255239
Gedeborg R, Garmo H, Robinson D, et al. Prescription-based prediction of baseline mortality risk among older men. PLoS One. 2020;15(10):e0241439.
https://doi.org/10.1371/journal.pone.0241439 DOI: https://doi.org/10.1371/journal.pone.0241439
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
https://doi.org/10.1016/0197-2456(96)00075-X DOI: https://doi.org/10.1016/0197-2456(96)00075-X
Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191–192.
https://doi.org/10.1200/JCO.1991.9.1.191 DOI: https://doi.org/10.1200/JCO.1991.9.1.191
Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70:i08.
https://doi.org/10.18637/jss.v070.i08 DOI: https://doi.org/10.18637/jss.v070.i08
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
https://doi.org/10.1186/1471-2458-11-450 DOI: https://doi.org/10.1186/1471-2458-11-450
Godtman R, Holmberg E, Stranne J, et al. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45(4):226–232.
https://doi.org/10.3109/00365599.2011.559950 DOI: https://doi.org/10.3109/00365599.2011.559950
Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
https://doi.org/10.1080/02841860802247664 DOI: https://doi.org/10.1080/02841860802247664
Hussain M, Fizazi K, Shore ND, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10(6):807–820.
https://doi.org/10.1001/jamaoncol.2024.0591 DOI: https://doi.org/10.1001/jamaoncol.2024.0591
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–1216.
https://doi.org/10.1016/S0140-6736(20)30314-7 DOI: https://doi.org/10.1016/S0140-6736(20)30314-7
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Paolo Zaurito, Rolf Gedeborg, Hans Garmo, Eugenio Ventimiglia, Mats Alhberg, Pär Stattin, Marcus Westerberg
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
